

# CITATION REPORT

List of articles citing

**Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension**

**DOI: 10.1183/13993003.02044-2014**

**European Respiratory Journal, 2015, 46, 405-13.**

**Source:** <https://exaly.com/paper-pdf/62106385/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
169	AMBITION: An important piece in the therapeutic puzzle of pulmonary arterial hypertension. <b>2015</b> , 2015, 48		
168	Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 297-8	13.6	3
167	The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 879-82	13.6	47
166	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). <i>European Respiratory Journal</i> , <b>2015</b> , 46, 903-75	13.6	1672
165	A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy. <b>2016</b> , 5,		12
164	New Therapeutic Paradigms and Guidelines in the Management of Pulmonary Arterial Hypertension. <b>2016</b> , 22, S3-21		11
163	Future perspectives in pulmonary arterial hypertension. <b>2016</b> , 25, 381-389		14
162	Beyond a single pathway: combination therapy in pulmonary arterial hypertension. <b>2016</b> , 25, 408-417		38
161	Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <b>2016</b> , 102 Suppl 2, ii67-85		43
160	The effects of pulmonary vasodilating agents on right ventricular parameters in severe group 3 pulmonary hypertension: a pilot study. <i>Pulmonary Circulation</i> , <b>2016</b> , 6, 524-531	2.7	6
159	Update on pulmonary arterial hypertension pharmacotherapy. <b>2016</b> , 128, 460-73		14
158	Independence Day: Separating Right Ventricular Function From Pulmonary Arterial Hypertension in Systemic Sclerosis. <b>2016</b> , 133, 2345-7		5
157	Pulmonary hypertension. <b>2016</b> , 25, 4-11		27
156	Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials. <i>Chest</i> , <b>2016</b> , 150, 353-66	5.3	32
155	Contemporary diagnosis and management of pulmonary hypertension. <b>2016</b> , 102, 1680-91		3
154	[Pulmonary hypertension : What is new in therapy?]. <b>2016</b> , 65, 635-52		1
153	A Contemporary Approach to Pulmonary Arterial Hypertension. <b>2016</b> , 18, 58		1

152	Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. <b>2016</b> , 9, 29-35		4
151	[Targeted therapy of pulmonary arterial hypertension: Recommendations of the Cologne Consensus Conference 2016]. <b>2016</b> , 141, S33-S41		12
150	New paradigm for pulmonary arterial hypertension treatment. <b>2016</b> , 22, 429-33		4
149	Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis. <b>2016</b> , 59, 8168-88		17
148	Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. <b>2016</b> , 32, 1520-1530		39
147	Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar. <b>2016</b> , 69, 177.e1-177.e62		137
146	Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). <b>2016</b> , 18, 10		28
145	Treatment of pulmonary hypertension. <b>2016</b> , 4, 323-36		75
144	Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. <b>2016</b> , 4, 291-305		133
143	Update in treatment options in pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2016</b> , 35, 695-703	5.8	18
142	Combination or monotherapy for pulmonary arterial hypertension?. <b>2016</b> , 4, 247-9		2
141	Upfront combination therapy: does the AMBITION study herald a new era in the treatment of pulmonary arterial hypertension?. <b>2016</b> , 71, 107-9		5
140	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung		3455
139	Pulmonary hypertension in connective tissue diseases: an update. <i>International Journal of Rheumatic Diseases</i> , <b>2017</b> , 20, 5-24	2.3	26
138	Ambrisentan: a review of its use in pulmonary arterial hypertension. <b>2017</b> , 11, 233-244		12
137	Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment. <b>2017</b> , 94, 26-37		15
136	Novelties in the Treatment of Pulmonary Hypertension. <b>2017</b> , 53, 235-236		
135	Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1). <b>2017</b> , 126, 84-92		10

134	Identifying "super responders" in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2017</b> , 7, 300-311	7
133	Epidemiology and treatment of pulmonary arterial hypertension. <b>2017</b> , 14, 603-614	182
132	Outcomes of pulmonary arterial hypertension therapy in Australia: is monotherapy adequate?. <b>2017</b> , 47, 1124-1128	
131	Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. <i>Pulmonary Circulation</i> , <b>2017</b> , 7, 312-325	2.7 35
130	Novelties in the Treatment of Pulmonary Hypertension. <b>2017</b> , 53, 235-236	2
129	Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities. <b>2017</b> , 8, 47-64	19
128	Treatment of pulmonary arterial hypertension in Eisenmenger syndrome: Practice makes (almost) perfect. <i>Journal of Heart and Lung Transplantation</i> , <b>2017</b> , 36, 376-377	5.8
127	Medical Treatment of Pulmonary Arterial Hypertension. <b>2017</b> , 38, 686-700	6
126	[Update pulmonary arterial hypertension : Definitions, diagnosis, therapy]. <b>2017</b> , 58, 937-957	5
125	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6 74
124	Effect of Body Position, Exercise, and Sedation on Estimation of Pulmonary Artery Pressure in Dogs with Degenerative Atrioventricular Valve Disease. <b>2017</b> , 31, 1611-1621	10
123	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6 288
122	The Management of Pulmonary Arterial Hypertension in the Setting of Systemic Sclerosis. <b>2017</b> , 411-419	
121	A review of therapeutic agents for the management of pulmonary arterial hypertension. <b>2017</b> , 11, 46-63	8
120	The evolving landscape of combination therapy for pulmonary arterial hypertension. <b>2017</b> , 11, 91-95	1
119	Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis. <i>Chest</i> , <b>2017</b> , 151, 90-105	5.3 31
118	Incidence and risk of respiratory tract infection associated with specific drug therapy in pulmonary arterial hypertension: a systematic review. <b>2017</b> , 7, 16218	11
117	The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease. <b>2017</b> , 6,	9

116	Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials. <b>2017</b> , 11, 871-885		12
115	Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. <b>2017</b> , 9, 731-739		13
114	Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. <b>2017</b> , 17, 239		19
113	Nitric oxide and pulmonary arterial hypertension. <b>2017</b> , 2017, 14		21
112	Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study. <b>2018</b> , 17, 612-618		3
111	Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A systemic review and meta-analysis. <b>2018</b> , 12, 2065-2074		11
110	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <b>2018</b> , 71, 752-763		50
109	Lessons from the COMPASS-3 Study. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045893218757100	2.7	
108	Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial. <b>2018</b> , 18, 1-11		22
107	Trial Duration and Risk Reduction in Combination Therapy Trials for Pulmonary Arterial Hypertension: A Systematic Review. <i>Chest</i> , <b>2018</b> , 153, 1142-1152	5.3	3
106	Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodyNamic long-term efficacy (ITALY study). <b>2018</b> , 19, 12-17		15
105	Pulmonary arterial hypertension: pathogenesis and clinical management. <b>2018</b> , 360, j5492		312
104	No, we are not-we keep forgetting the right ventricle. <b>2018</b> , 74, 141-143		1
103	Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045893217741480	2.7	7
102	Pulmonary vasodilation by phosphodiesterase 5 inhibition is enhanced and nitric oxide independent in early pulmonary hypertension after myocardial infarction. <b>2018</b> , 314, H170-H179		7
101	Efficacy and tolerability of pharmacological interventions for pulmonary arterial hypertension: A network meta-analysis. <b>2018</b> , 50, 1-10		5
100	Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension. <b>2018</b> , 43, 191-216		1
99	A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension. <i>Drug Delivery</i> , <b>2018</b> , 25, 1898-1909	7	10

98	Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. <b>2018</b> , 272S, 37-45		33
97	Interpreting risk reduction in clinical trials for pulmonary arterial hypertension. <b>2018</b> , 27,		2
96	Aggressive combination therapy for treatment of systemic sclerosis-associated pulmonary hypertension.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2018</b> , 3, 30-38	2.3	2
95	Non-invasive right ventricular load adaptability indices in patients with scleroderma-associated pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045894018788268	2.7	18
94	Right Ventricle Remodeling and Function in Scleroderma Patients. <b>2018</b> , 2018, 4528148		4
93	Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045894018792501	2.7	7
92	Pulmonary Arterial Hypertension: Pathophysiology and Treatment. <b>2018</b> , 6,		50
91	Major lung complications of systemic sclerosis. <b>2018</b> , 14, 511-527		43
90	Efficacy and safety of oral targeted therapies in pulmonary arterial hypertension: a meta-analysis of randomized clinical trials. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045894018798183	2.7	3
89	Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis. <b>2019</b> , 39, 1031-1044		4
88	Combination Therapy in Pulmonary Arterial Hypertension: Gleaning a Practical Approach from the Randomized Trials. <b>2019</b> , 28, 93-99		
87	A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension. <b>2019</b> , 9, 239-249		5
86	Pharmacotherapy for pulmonary arterial hypertension. <b>2019</b> , 11, S1767-S1781		27
85	Pulmonary Arterial Hypertension and Therapeutic Interventions. <b>2019</b> , 28, 80-92		3
84	A modeling and simulation-based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension. <b>2019</b> , 46, 499-509		2
83	Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment. <b>2019</b> , 244, 120-131		16
82	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. <b>2019</b> , 12, e005095		5
81	Pulmonary Arterial Hypertension in HIV. <b>2019</b> , 159-170		

80	Cardiovascular Care in Patients With HIV. <b>2019</b> ,			1
79	2018 TSOE guideline focused update on diagnosis and treatment of pulmonary arterial hypertension. <b>2019</b> , 118, 1584-1609			11
78	Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). <b>2019</b> , 83, 842-945			67
77	Berberine attenuates hypoxia-induced pulmonary arterial hypertension via bone morphogenetic protein and transforming growth factor- $\beta$ signaling. <b>2019</b> , 234, 17482-17493			17
76	Treatment of pulmonary arterial hypertension: A review of drugs available for advanced therapy. <b>2019</b> , 25,			
75	Phosphodiesterase 5 inhibitors for pulmonary hypertension. <i>The Cochrane Library</i> , <b>2019</b> , 1, CD012621	5.2		32
74	Sildenafil for Pulmonary Arterial Hypertension. <b>2019</b> , 26, e520-e526			19
73	Pulmonary arterial hypertension populations of special interest: portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease. <b>2019</b> , 21, K37-K45			8
72	[Systemic sclerosis]. <b>2019</b> , 60, 1251-1269			4
71	Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension-related hospitalization in the AMBITION trial. <i>Journal of Heart and Lung Transplantation</i> , <b>2019</b> , 38, 194-202	5.8		9
70	Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database. <i>Pulmonary Circulation</i> , <b>2019</b> , 9, 2045894018816294	2.7		12
69	Pulmonary arterial hypertension in systemic sclerosis: Diagnosis and treatment according to the European Society of Cardiology and European Respiratory Society 2015 guidelines.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2019</b> , 4, 35-42	2.3		9
68	Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. <i>Chest</i> , <b>2019</b> , 155, 565-586	5.3		126
67	Advances in medical therapy for pulmonary arterial hypertension. <i>Current Opinion in Cardiology</i> , <b>2019</b> , 34, 98-103	2.1		6
66	Risk stratification and medical therapy of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6		316
65	Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 89-98	4.1		7
64	EXPRESS: Switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH. <i>Pulmonary Circulation</i> , <b>2019</b> , 2045894019837849	2.7		1
63	A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension. <i>Annals of Pharmacotherapy</i> , <b>2020</b> , 54, 423-433	2.9		2

62	Prognostic value of six-minute walk distance at a South American pulmonary hypertension referral center. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894019888422	2.7	1
61	Pharmacologic therapy for pulmonary artery hypertension. <i>Current Opinion in Cardiology</i> , <b>2020</b> , 35, 643-656		1
60	Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020962960	2.7	4
59	Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis. <i>International Journal of Rheumatic Diseases</i> , <b>2020</b> , 23, 1276-1287	2.3	1
58	Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020943523	2.7	3
57	Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020933291	2.7	3
56	Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal. <i>BMC Pulmonary Medicine</i> , <b>2020</b> , 20, 202	3.5	0
55	Advanced Diagnosis and Therapy for Pulmonary Arterial Hypertension. <i>Nano LIFE</i> , <b>2020</b> , 10, 2040003	0.9	2
54	Risk stratification in chronic thromboembolic pulmonary hypertension predicts survival. <i>Scandinavian Cardiovascular Journal</i> , <b>2021</b> , 55, 43-49	2	6
53	Management of Pulmonary Arterial Hypertension. <i>Current Cardiovascular Risk Reports</i> , <b>2021</b> , 15, 2	0.9	13
52	Improved low-risk criteria scores for combination therapy of sildenafil and generic bosentan in patients with congenital heart disease with severe pulmonary hypertension: A prospective open label study. <i>JRSM Cardiovascular Disease</i> , <b>2021</b> , 10, 2048004020982213	1.1	1
51	[Organ Bath Experiments on Human Pulmonary Vessels: Assessment of Drug Efficacy for Treatment of Pulmonary Arterial Hypertension]. <i>Pneumologie</i> , <b>2021</b> , 75, 369-376	0.5	
50	Endothelin receptor antagonists for pulmonary arterial hypertension. <i>The Cochrane Library</i> , <b>2021</b> , 3, CD014434	0.4	1
49	Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 837-847	9.5	9
48	Life-threatening PPHN refractory to nitric oxide: proposal for a rational therapeutic algorithm. <i>European Journal of Pediatrics</i> , <b>2021</b> , 180, 2379-2387	4.1	7
47	A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome. <i>Indian Heart Journal</i> , <b>2021</b> , 73, 633-636	1.6	1
46	Group 1 Clinical Features and Treatment. <b>2022</b> , 616-632		
45	Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis. <i>Drug Delivery</i> , <b>2021</b> , 28, 1007-1019	7	2



44	Pulmonary arterial hypertension specific therapy: The old and the new. <i>Pharmacology &amp; Therapeutics</i> , <b>2020</b> , 214, 107576	13.9	16
43	Review of the diagnosis and pharmacological management of pulmonary arterial hypertension in connective tissue disease. <i>Hong Kong Bulletin on Rheumatic Diseases</i> , <b>2016</b> , 16, 14-22		1
42	Riociguat and sildenafil for pulmonary hypertension: similarity and difference. <i>Pulmonologiya</i> , <b>2016</b> , 26, 85-91	0.8	4
41	Treatment Considerations for Pulmonary Arterial Hypertension and Assessment of Treatment Response. <i>Advances in Pulmonary Hypertension</i> , <b>2018</b> , 16, 120-124	0.5	1
40	New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension. <i>Current Medicinal Chemistry</i> , <b>2019</b> , 26, 2844-2864	4.3	11
39	Pulmonary Hypertension. <i>Deutsches A&amp;#x0308;rztblatt International</i> ,	2.5	12
38	Pulmonary Hypertension. <i>Deutsches A&amp;#x0308;rztblatt International</i> , <b>2017</b> , 114, 73-84	2.5	57
37	Evidence base for specific pulmonary vasodilators in adults with congenital heart disease. <i>Terapevticheskii Arkhiv</i> , <b>2021</b> , 93, 1106-1116	0.9	1
36	Cardiovascular Diseases That Have Emerged From the Darkness. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021095	6	3
35	What do the "new" Pulmonary Hypertension Guidelines tell us: should we change our practice?. <i>Anatolian Journal of Cardiology</i> , <b>2015</b> , 15, 890-2	0.8	
34	Management of the Scleroderma Patient with Pulmonary Arterial Hypertension Failing Initial Therapy. <b>2017</b> , 691-700		
33	Gaps and Controversies of New Treatment Recommendations in Recent Pulmonary Hypertension Guidelines: What We Know and What We Don't. <i>Advances in Pulmonary Hypertension</i> , <b>2017</b> , 16, 20-25	0.5	
32	Whatever Happened to Oral Monotherapy?. <i>Advances in Pulmonary Hypertension</i> , <b>2017</b> , 15, 190-192	0.5	
31	Selection of Infusion Prostacyclin Therapy in Pulmonary Arterial Hypertension: Not Just a Last Resort. <i>Advances in Pulmonary Hypertension</i> , <b>2017</b> , 16, 14-19	0.5	
30	Medikamente bei pulmonal-arterieller Hypertonie. <b>2017</b> , 39,		
29	Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment. <i>Systemic Hypertension</i> , <b>2018</b> , 15, 66-71	1.6	1
28	Goal-Oriented Sequential Combination Therapy Evaluated Using Cardiopulmonary Exercise Parameters for the Treatment of Newly Diagnosed Pulmonary Arterial Hypertension - Goal-Oriented Therapy Evaluated by Cardiopulmonary Exercise Testing for Pulmonary Arterial Hypertension (GOOD EYE). <i>Circulation Reports</i> , <b>2019</b> , 1, 303-311	0.7	1
27	[A systematic review as a method of gathering scientific evidence into clinical guidelines: CHEST-2019 guideline for the therapy pulmonary arterial hypertension in adults]. <i>Terapevticheskii Arkhiv</i> , <b>2019</b> , 91, 105-114	0.9	1

26	Selexipag for the treatment of pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 583-595	3.8	1
25	[Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia]. <i>Terapevticheskii Arkhiv</i> , <b>2020</b> , 92, 80-85	0.9	5
24	Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 767002	5.6	4
23	The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	1
22	2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. <i>Russian Journal of Cardiology</i> , <b>2022</b> , 26, 4683	1.3	9
21	Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis.. <i>Journal of Heart and Lung Transplantation</i> , <b>2022</b> ,	5.8	0
20	Therapeutic approaches to improve pulmonary arterial load and right ventricular pulmonary arterial coupling. <b>2022</b> , 935-958		
19	Dan-Shen-Yin Granules Prevent Hypoxia-Induced Pulmonary Hypertension STAT3/HIF-1 $\alpha$ /VEGF and FAK/AKT Signaling Pathways.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 844400	5.6	2
18	Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.. <i>JAMA - Journal of the American Medical Association</i> , <b>2022</b> , 327, 1379-1391	27.4	9
17	The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future.. <i>Pharmacology &amp; Therapeutics</i> , <b>2022</b> , 108192	13.9	1
16	Subgroup Analysis in Pulmonary Hypertension-Specific Therapy Clinical Trials: A Systematic Review. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12, 863	3.6	0
15	Research Advances in ET-1 Antagonistic Drugs in the Treatment of Pulmonary Hypertension. <i>Advances in Clinical Medicine</i> , <b>2022</b> , 12, 4711-4715	0	
14	Drug-Drug Interactions in the Management of Patients with Pulmonary Arterial Hypertension. <i>Chest</i> , <b>2022</b> ,	5.3	0
13	General independent censoring in event-driven trials with staggered entry. <i>Biometrics</i> ,	1.8	1
12	Effects of oral targeted treatments in pulmonary arterial hypertension: A systematic review and meta-analysis. 9,		
11	Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <b>2022</b> , 146, 597-612		0
10	Targeted therapies in patients with pulmonary arterial hypertension due to congenital heart disease. <b>2022</b> , 20,		
9	Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis. <b>2022</b> , 31, 220036		1

- 8 Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials. **2022**, 76, 102144
- 7 Efficacy of Commonly Targeted Drugs versus Pulmonary Artery Denervation for Pulmonary Hypertension: A Systematic Review. **2022**, 12, 6943-6952 ○
- 6 Strategizing Drug Therapies in Pulmonary Hypertension for Improved Outcomes. **2022**, 15, 1242 2
- 5 Patient-specific and gene-corrected induced pluripotent stem cell-derived endothelial cells elucidate single-cell phenotype of pulmonary veno-occlusive disease. **2022**, ○
- 4 The evolving landscape of pulmonary arterial hypertension clinical trials. **2022**, 400, 1884-1898 ○
- 3 Combination therapy of newly diagnosed intermediate-risk pulmonary arterial hypertension: A review. **2022**, 24, 688-695 ○
- 2 Adherence and treatment patterns of disease-specific drugs among patients with pulmonary arterial hypertension: A nationwide, new-user cohort study. 13, ○
- 1 Bosentan Is Associated with a Reduction in Right Ventricular Systolic Pressure N-Terminal Pro-Hormone B-Type Natriuretic Peptide Levels in Young Patients with Pulmonary Hypertension. **2023**, 13, 32-42 ○